Abstract
Eighty percent of patients with cystic fibrosis (CF) become colonized with Pseudomonas aeruginosa. Systemic aminoglycosides are the standard treatment, but administration by inhalation could deliver high antibiotic concentrations directly to infected endobronchial tissue with minimal systemic exposure and toxicity. A preservative-free formulation of tobramycin for inhalation, developed to avoid bronchoconstriction and side effects …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
